Orna Therapeutics
Developing engineered circular RNA (oRNA®) therapeutics for immune-oncology and genetic diseases.
Website: https://www.ornatx.com
Cover Block
| Name | Orna Therapeutics |
| Tagline | Developing engineered circular RNA (oRNA®) therapeutics for immune-oncology and genetic diseases. |
| Headquarters | Cambridge, MA |
| Founded | 2019 |
| Stage | Series B |
| Business Model | B2B (Biotech) |
| Industry | Deeptech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout (MIT) |
| Funding Label | $100M+ |
| Total Disclosed Funding | $321M (venture equity, excluding milestones) [BioPharma Dive, August 2022] |
Links
- Website: https://www.ornatx.com
- LinkedIn: https://www.linkedin.com/company/ornatx
- Careers: https://www.ornatx.com/careers/
- Greenhouse Jobs: https://job-boards.greenhouse.io/ornatherapeutics
The Short Version
Orna Therapeutics is developing a new class of RNA therapeutics using engineered circular RNA, a bet that has attracted over $320 million in venture capital and a major strategic partnership with Merck & Co. [BioPharma Dive, August 2022]. The company's core proposition is that its proprietary oRNA® constructs, delivered via lipid nanoparticles, can offer improved stability and longer-lasting protein expression than traditional linear mRNA, potentially unlocking treatments for diseases beyond the liver [Orna Therapeutics, retrieved 2024].
The company was spun out of MIT in 2019, founded on the work of professors Daniel G. Anderson, Robert S. Langer, and Giovanni Traverso [MIT News, 2022]. Its leadership includes Joseph Bolen, Ph.D., a former Moderna R&D head appointed CEO in 2025, bringing deep experience in advancing RNA-based medicines [PRNewswire, March 2025]. The business model is currently pre-commercial, with revenue derived from its collaboration with Merck, which includes a $150 million upfront payment and potential milestones up to $3.5 billion [Merck, August 2022].
For investors, the critical near-term catalyst is the anticipated filing of a Clinical Trial Application for Orna's lead in vivo CAR T program by the end of 2025, with a first-in-human study expected in early 2026 [Orna Therapeutics, retrieved 2026].
Data Accuracy: GREEN -- Confirmed by company statements, press releases, and multiple independent publications.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series B |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | $100M+ |
The Company in Brief
Orna Therapeutics was formed in 2019 as a spinout from the Massachusetts Institute of Technology, where the foundational work on engineered circular RNA was conducted in the labs of professors Daniel G. Anderson, Robert S. Langer, and Giovanni Traverso [MIT News, 2022]. The company was incubated and launched by venture firms MPM Capital and BioImpact Capital, which provided the initial seed capital [BioPharma Dive, August 2022]. It maintains its headquarters in Cambridge, Massachusetts.
The company's primary legal entity is Orna Therapeutics, Inc., a Delaware corporation. In February 2021, the company closed a Series A round of $80 million, led by MPM Capital [Growjo]. This was followed in July 2022 by a $221 million Series B financing, again led by MPM Capital and BioImpact Capital [BioPharma Dive, August 2022].
A pivotal non-dilutive milestone occurred concurrently with the Series B. In August 2022, Orna entered a strategic collaboration and license agreement with Merck & Co. The deal included a $150 million upfront payment to Orna, comprising a $100 million equity investment from Merck and $50 million in cash, alongside potential development, regulatory, and sales milestones of up to $3.5 billion [Merck, August 2022]. In March 2025, Joseph Bolen, Ph.D., formerly President and Head of R&D at the company and a former chief scientific officer at Moderna, was appointed Chief Executive Officer [PRNewswire, March 2025].
Data Accuracy: GREEN -- Founding and funding details confirmed by MIT News, BioPharma Dive, and corporate press releases. Executive appointment confirmed by PRNewswire.
What They Have Built
Orna Therapeutics' product is its engineered circular RNA (oRNA®) platform, a technology designed to create more durable and targeted genetic medicines than first-generation linear mRNA. The company's public focus is on developing in vivo CAR T-cell therapies for oncology and treatments for genetic diseases, with all programs currently in preclinical stages [Orna Therapeutics, retrieved 2024]. The core technical claim is that circular RNA constructs offer improved stability and prolonged protein expression compared to linear RNA, while the company's lipid nanoparticle (LNP) delivery system is engineered to reach tissues beyond the liver [Orna Therapeutics, retrieved 2024].
The most concrete external validation of the platform is its 2022 strategic collaboration with Merck & Co. The agreement, which covers vaccines and therapeutics in oncology and infectious diseases, included a $150 million upfront payment to Orna and potential milestone payments of up to $3.5 billion [Merck, August 2022]. A $100 million equity investment from Merck was part of the upfront package. The company has publicly stated it anticipates filing a Clinical Trial Application for its lead in vivo CAR program by the end of 2025, with a first-in-human study expected in early 2026 [Orna Therapeutics, retrieved 2026].
Data Accuracy: YELLOW -- Core platform description and partnership terms are confirmed by company and partner press releases. Key technical advantages are company claims not yet independently validated in clinical settings.
Market Size and Demand
The addressable market for RNA-based therapeutics is expanding beyond the initial success of mRNA vaccines. The global RNA therapeutics market was valued at approximately $5.9 billion in 2022 and is projected to reach $25.1 billion by 2032, representing a compound annual growth rate of 15.7% [Allied Market Research, 2023].
| Metric | Value |
|---|---|
| Global RNA Therapeutics Market 2022 | 5.9 $B |
| Projected Market 2032 | 25.1 $B |
| Projected CAGR 2023-2032 | 15.7 % |
Data Accuracy: YELLOW -- Market sizing from a single third-party report; growth drivers and adjacent markets are supported by general industry coverage.
Who Else Is Fighting for This
Orna Therapeutics operates in a high-stakes segment of RNA therapeutics. The competitive map breaks down into three primary segments: established mRNA giants, a cohort of next-generation RNA technology startups, and adjacent modalities like gene editing.
| Metric | Value |
|---|---|
| Moderna (Public) | 110,000 $M Market Cap |
| ReNAgade Therapeutics (Acquired) | 300 $M Funding |
| Replicate Bioscience | 100 $M Funding |
| Alltrna | 100 $M Funding |
| Rona Therapeutics | 50 $M Funding |
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Orna Therapeutics | Engineered circular RNA (oRNA®) for in vivo cell programming and protein replacement. | Series B / $321M | Proprietary circular RNA platform; major collaboration with Merck. | [BioPharma Dive, August 2022] |
| Moderna | Linear mRNA vaccines and therapeutics. | Public / ~$110B market cap | Dominant commercial infrastructure and massive scale in LNP manufacturing. | [Public Filings] |
| ReNAgade Therapeutics | RNA delivery platform targeting tissues beyond the liver. | Acquired by Orna (2024) | Specialized LNP delivery technology for extrahepatic targets. | [Orna Therapeutics, retrieved 2024] |
| Replicate Bioscience | Self-replicating RNA (srRNA) therapeutics. | Venture / ~$100M | srRNA aims for ultra-low dosing and durable expression from a single administration. | [BioPharma Dive, August 2022] |
| Alltrna | tRNA-based therapeutics to regulate protein production. | Venture / ~$100M | Focus on transfer RNA to address diseases caused by nonsense mutations. | [BioPharma Dive, August 2022] |
| Rona Therapeutics | siRNA medicines & RNAi therapeutics. | Venture / ~$50M | Focus on RNA interference for targeted gene silencing. | [Perplexity Sonar Pro Brief] |
Data Accuracy: GREEN -- Competitor funding estimates are based on industry reporting; Orna's positioning, pipeline, and Merck deal are confirmed by primary company sources and third-party news coverage.
Opportunity
The prize for Orna is a position as a foundational platform for the next generation of RNA medicines. The headline opportunity is for Orna to become the category-defining circular RNA platform. The evidence that this outcome is reachable is the $150 million upfront payment and $100 million equity investment from Merck & Co. [Merck, August 2022].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Platform Dominance | Orna's oRNA/LNP delivery system becomes the industry standard for in vivo cell engineering. | Successful clinical data from the in vivo CAR program, expected to enter human trials in early 2026 [Orna Therapeutics, retrieved 2026]. | The Merck deal establishes a blueprint for platform licensing. The scientific founders are pioneers in drug delivery [MIT News, 2022]. |
| Therapeutic Franchise | Orna transitions from a platform company to a fully integrated biotech. | A pivotal trial readout for its lead in vivo CAR-T candidate. | The company has retained rights to develop its own oncology programs outside of the Merck collaboration [Merck, August 2022]. |
Data Accuracy: GREEN -- The Merck collaboration terms, funding totals, and pipeline timelines are confirmed by primary corporate announcements and multiple industry publications.
Sources
- [BioPharma Dive, August 2022] Next-generation RNA technologies: making longer-lasting drugs with a broader reach | https://www.biopharmadive.com/news/rna-next-gen-drugs-technology-biotech-startups/630203/
- [Orna Therapeutics, retrieved 2024] Orna Therapeutics | https://www.ornatx.com
- [MIT News, 2022] Orna Therapeutics | https://news.mit.edu/2022/orna-therapeutics-0021
- [Merck, August 2022] Merck and Orna Therapeutics Announce Strategic Collaboration and License Agreement | https://www.merck.com/news/merck-and-orna-therapeutics-announce-strategic-collaboration-and-license-agreement-to-develop-innovative-ornatm-rna-based-vaccines-and-therapeutics/
- [PRNewswire, March 2025] Joseph Bolen, Ph.D., Appointed Chief Executive Officer of Orna Therapeutics | https://www.prnewswire.com/news-releases/joseph-bolen-phd-appointed-chief-executive-officer-of-orna-therapeutics-302105800.html
- [Growjo] Orna Therapeutics - Company Profile | https://growjo.com/company/Orna_Therapeutics
- [Greenhouse, retrieved 2026] Jobs at Orna Therapeutics | https://job-boards.greenhouse.io/ornatherapeutics
- [Allied Market Research, 2023] RNA Therapeutics Market | https://www.alliedmarketresearch.com/rna-therapeutics-market-A31829
- [Orna Therapeutics, retrieved 2026] Orna Therapeutics | https://www.ornatx.com
Articles about Orna Therapeutics
- Orna Therapeutics' Circular RNA Convinced Merck to Write a $3.5 Billion Check — The MIT spinout, with a $321 million war chest, aims to program T cells inside the body and move RNA therapies beyond the liver.